21/04/2017 18:39:45

MPI increases its share capital with nominal DKK 6,190 as a result of exercise of 123,800 warrants

Hoersholm; April 21st 2017 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of an exercise of warrants the share capital has been increased by nominal DKK 6,190 and the number of shares has been increased with 123,800.

The increase is affected without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share of nominally DKK 0.05.

Proceeds to the company are DKK 64,376.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. MPI's current share capital amounts to DKK 1,174,452 and will after the capital increase be DKK 1,180,642. The capital increase is expected to be finalized shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)

MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.

The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI

Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:

CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication

E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com

Telephone: +45 21 60 89 22                                                                       Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 21

st

2017.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - Increases its share capital due to warrant exercise April 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medical Prognosis Institute via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
21 Apr
PNDORA
Du er dødbringende for EI, Goodwrench. Man gider snart ikke læse med mere, når du forurener/destruer..
31
25 Apr
PNDORA
Her er de aktier der har min opmærksomhed... Bemærk en gang iskoldt overblik og common sense er i sp..
29
24 Apr
BAVA
  Tirsdag 25/4 generalforsamling Torsdag den 4/5 Q1 regnskab   Vi har den 1/5 om fire børsdage, ge..
18
23 Apr
PNDORA
  Det meste tyder i mine øjne på, at Pandora showet fortsætter næste uge med nye fald.       Jeg ove..
17
22 Apr
 
Manden kommer med noget helt reelt, som kan diskuteres. I stedet bliver der svaret på sædvanlig EI ..
17
25 Apr
 
Den stenrige Baron lå for døden. Men han nåede at få solgt alle sine aktier og lavede en aftale med ..
16
23 Apr
OMXC25
Har i bemærket, at de skribenter, der skriver de værste svinere, har fået flest grønne tommelfingre?..
16
21 Apr
PNDORA
Jeg har netop fået email fra ABG om at Maverick har trukket følehornene til sig. Short-præsentatione..
16
27 Apr
BAVA
Det er naturligvis helt valide overvejelser du gør dig, og man burde faktisk gøre sig lignende overv..
13
26 Apr
ZEAL
Den kommer her Jacob - og da ganske interessant læsning! Zealand-chef løfter sløret for markedsføri..
13

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

27/04/2017 15:52:23
*** AMENDS PREVIOUS DISCLOSURE *** FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   ..

Alliance Trust PLC : Net Asset Value(s)

27/04/2017 13:47:13
ALLIANCE TRUST PLC                                    At the close of business on Wednesday 26 April 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 721.0p -       including income, 728.5p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Admiral Group PLC : Result of AGM

27/04/2017 09:21:14
  ANNUAL GENERAL MEETING RESULT The 2017 Annual General Meeting of Admiral Group Plc was held at Cardiff City Hall, Cardiff, CF10 3ND on Wednesday 26th April 2017 at 2:00pm. All resolutions were decided on a poll and all resolutions proposed at the Meeting were passed.   Resolutions Votes For ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Hamilton Thorne Reports Record Revenue Growth for Quarter and Year-Ended December 31, 2016
2
Check Point Software Technologies Reports First Quarter 2017 Financial Results
3
Thinfilm Readies for Industrial IoT Market Through Key Partnerships with Socket Mobile, Famoco, and SpringCard
4
Admiral Group PLC : Result of AGM
5
SDRL - Filing of 2016 Annual Report on Form 20-F

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
28 April 2017 07:17:49
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseCandidateBuild_20170427.1 - EUROWEB5 - 2017-04-28 08:17:49 - 2017-04-28 07:17:49 - 1000 - Website: OKAY